Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial
Titel:
Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial
Auteur:
Zinzani, Pier Luigi Khuageva, Nuriet K Wang, Huaqing Garicochea, Bernardo Walewski, Jan Van Hoof, Achiel Soubeyran, Pierre Caballero, Dolores Buckstein, Rena Esseltine, Dixie-Lee Theocharous, Panteli Enny, Christopher Zhu, Eugene Elsayed, Yusri A Coiffier, Bertrand